Summary
Bristol-Myers Squibb Company (BMY) reported strong sales growth of 15% in 2003, reaching $20.9 billion, driven by robust performance in key products like Pravachol and Plavix. The company also highlighted a significant increase in earnings from continuing operations, up 50% year-over-year, reflecting improved sales and a reduction in specific charges incurred in the prior year. Despite these positive trends, investors should note the company is undergoing a financial restatement impacting prior periods, primarily to correct accounting policies and errors. While management is actively addressing internal control improvements, a 'reportable condition' in income tax accounting remains, with remediation expected by year-end 2004. The company also faces ongoing litigation, particularly concerning the patent for Plavix, which could materially impact future results if an adverse outcome occurs.
Key Highlights
- 1BMY reported a 15% increase in net sales for 2003, reaching $20.9 billion, with strong performance from key products Pravachol and Plavix.
- 2Earnings from continuing operations saw a significant 50% increase in 2003, reaching $3,106 million, with diluted EPS rising to $1.59.
- 3The company is restating financial statements for prior periods to correct accounting policies and errors, impacting comparability.
- 4Significant investments were made in R&D, totaling $2.3 billion in 2003, reflecting a commitment to pipeline development.
- 5The company has a strong international presence, with international sales increasing 18% in 2003, benefiting from favorable foreign exchange rates.
- 6Significant legal proceedings are ongoing, most notably patent litigation for Plavix, which could materially impact future financial results.
- 7Improvements in internal controls are underway, addressing previously identified material weaknesses, though a 'reportable condition' in income tax accounting persists.